X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vaxart is developing COVID-19 vaccine pill and is the first company to progress to a Phase II clinical trial with an oral candidate. Study will evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 old.
Lead Product(s): VXA-CoV2-1.1-S
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1.1-S
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Vaxart
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 30, 2022
Details:
HCT will allow AIM to expedite the development process for Ampligen by ensuring full exposure of both the control group and the Ampligen group, so as to assess whether there is a prophylactic effect.
Lead Product(s): Rintatolimod,Influenza Vaccine Live
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Aim ImmunoTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 30, 2021
Details:
The UK government has signed a contract to develop a COVID-19 human challenge study model, which would be the first of its kind in the world if it goes ahead.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: UK Government
Deal Size: $9.0 million Upfront Cash: $13.1 million
Deal Type: Agreement October 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
